Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies

ABSTRACT:

SUBMITTER: Chua L 

PROVIDER: S-EPMC12350181 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature